Cnbx Pharmaceuticals Inc. (CNBX) Stock Price & Analysis
Cnbx Pharmaceuticals Inc. (CNBX) rose 0.00% to USD 0 as of July 25, 2026 at 06:02 UTC, according to Nexqual real-time market data.
CNBX last closed at USD 0; the session ranged USD 0–0 on volume of 6,055,002 shares. Market capitalization is $160,576, with a 52-week range of USD 0–0 (OID). Source: Nexqual, July 25, 2026 at 06:02 UTC.
Key Statistics (as of July 25, 2026 at 06:02 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 6,055,002 shares |
| Market Cap | $160,576 |
| Exchange | OID |
Technical Analysis (CNBX)
Nexqual's technical model rates CNBX "STRONG SELL" based on 0 bullish and 4 bearish signals across 124 daily candles, as of July 25, 2026 at 06:02 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.61 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (CNBX)
Wall Street analysts rate CNBX "None", per Nexqual as of July 25, 2026 at 06:02 UTC.
| Consensus Rating | None |
|---|
Earnings (CNBX)
Source: Nexqual, July 25, 2026 at 06:02 UTC.
Financials & Fundamentals (CNBX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.01 |
| Total Cash | $9,487 |
| Total Debt | $1.17M |
| Free Cash Flow | $3,583 |
Source: Nexqual, July 25, 2026 at 06:02 UTC.
Financial Health Score (CNBX)
Nexqual rates Cnbx Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:02 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $9K cash vs $1M debt |
| Cash Flow | Weak — Operating cash flow -$154K |
| Efficiency | Mixed — No data |
Ownership (CNBX)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +6.23% |
| Shares Outstanding | 1.61B |
| Float | 1.61B |
Source: Nexqual, July 25, 2026 at 06:02 UTC.
Leadership (CNBX)
Cnbx Pharmaceuticals Inc. is led by Eyal Barad (age 60), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 06:02 UTC.
| Co-Founder, CEO & Director | Eyal Barad (age 60) |
|---|---|
| President, COO & Executive Chairman | Gabriel Yariv (age 49) |
| Chief Financial Officer | Uri Ben-Or (age 55) |
From Cnbx Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2025-12-01)
Key Strengths & Strategy (as disclosed to the SEC)
- CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.
- Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome.
- The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer.
- In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMMJ | American Cannabis Company, Inc. | USD 0 | ▲ 0% |
| OWCP | OWC PHARMACEUTICAL RESEARCH COR | USD 0 | ▲ 0% |
| DOGP | Dogecoin Cash Inc. | USD 0.01 | ▼ 7.23% |
| AXIM | Axim Biotechnologies, Inc. | USD 0 | ▲ 0% |
| CANN | TREES Corporation | USD 0.03 | ▲ 8.05% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:02 UTC. This page is informational and not investment advice.